| Title |
Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
|
|---|---|
| Published in |
Biologics: Targets & Therapy, December 2008
|
| DOI | 10.2147/btt.s3084 |
| Pubmed ID | |
| Authors |
David Kaminetzky, Kenneth B Hymes |
| Abstract |
Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is progression despite application of these treatments, or if the patient presents with a higher stage of disease, systemic chemotherapy or retinoids, rexinoids, biologic response modifiers are often necessary. Consequently, patients are often treated with a sequence of modalities and drugs. Denileukin diftitox (DD, Ontak(R)) is a targeted immunotoxin which has biological activity against malignancies expressing the IL-2 receptor. In addition to its unique mechanism of action, DD has a toxicity profile which does not overlap with most commonly used chemotherapeutic agents. CTCL/MF has been found be particularly susceptible to treatment with this agent. This review will describe the development DD, its proposed mechanism of action, the clinical trials which identified its utility in the treatment of CTCL/MF, the common toxicities encountered with this agent, and the management of these toxicities. In addition the incorporation of DD in the sequential treatment of CTCL/MF and data suggesting potential combination therapies employing this novel agent will be discussed. |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 23% |
| Student > Postgraduate | 2 | 15% |
| Student > Bachelor | 2 | 15% |
| Researcher | 2 | 15% |
| Other | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 2 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 38% |
| Biochemistry, Genetics and Molecular Biology | 2 | 15% |
| Agricultural and Biological Sciences | 2 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
| Chemical Engineering | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 2 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2022.
All research outputs
#8,616,072
of 25,576,801 outputs
Outputs from Biologics: Targets & Therapy
#108
of 274 outputs
Outputs of similar age
#51,757
of 180,437 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 8 outputs
Altmetric has tracked 25,576,801 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,437 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.